Showing 1221-1230 of 6040 results for "".
New Allergens Causing Contact Dermatitis
https://practicaldermatology.com/conferences/maui-derm-hawaii-2026/new-allergens-causing-contact-dermatitis/54644/Walter J. Liszewski, MD, discusses key takeaways from the “Contact Dermatitis Update 2026” session at Maui Derm Hawaii 2026.Clinical Data on Switching to Upadacitinib
https://practicaldermatology.com/series/updates-atopic-dermatitis/clinical-data-on-switching-to-upadacitinib/36534/Clinical investigator Christopher Bunick, MD, PhD, discusses results from the LEVEL UP trial among patients who switched from dupilumab to upadacitinib for atopic dermatitis.Are You Sure?
https://practicaldermatology.com/issues/april-2025/are-you-sure/35604/We are to treat patients in 3D, reminding them of the value of touch, of conversation, and of relationships. In the end, that’s what it’s all about.How to Ensure ‘People-First’ Content
https://practicaldermatology.com/issues/january-february-2025/how-to-ensure-people-first-content/32978/As members of the medical community, we have a strong sense of purpose and ethical responsibility to our patients and communities.Recap of Maui Derm Hawaii Meeting
https://practicaldermatology.com/series/dermwire-tv/recap-of-maui-derm-hawaii-meeting/32717/In this week's DermwireTV, key stakeholders in dermatology gather in Hawaii to discuss the latest developments and advances; a new review examines whether IgE-targeting therapies could represent a new treatment avenue for psoriasis and atherosclerosis; and the founder of SEEN hair care joSDPA: Dr. Matthew Zirwas Discusses Benefits of Attending the Annual Conference
https://practicaldermatology.com/conferences/sdpa-2024/sdpa-dr-matthew-zirwas-discusses-benefits-of-attending-the-annual-conference/29510/At the SDPA 22nd Annual Fall Dermatology Conference, Practical Dermatology caught up with Matthew Zirwas, MD. Dr. Zirwas shares why he looks forward to lecturing at the annual meeting.FDA Approves Bimzelx for Hidradenitis Suppurativa
https://practicaldermatology.com/series/dermwire-tv/fda-approves-bimzelx-hidradenitis-suppurativa/29518/In this week's DermwireTV, the FDA approves a new treatment for moderate to severe hidradenitis suppurativa; the FDA agrees to review the resubmission of Dupixent for the treatment of CSU; and the president of Merz Aesthetics, North America, joins us to discuss trends in the aesthetic market.FDA Approves Rosacea Treatment Emrosi
https://practicaldermatology.com/series/dermwire-tv/fda-approves-rosacea-treatment-emrosi/29207/In this week's DermwireTV, the FDA approves a first-of-its-kind treatment for rosacea in adults; two companies with approved atopic dermatitis products provide new long-term efficacy and safety data; and Andrew Mastro discusses how to recognize physician burnout.Significant FDA Approval for PDT
https://practicaldermatology.com/series/pdt-in-practice/significant-fda-approval-pdt/29102/Dr. Jonathan S. Weiss discusses the importance of a recent FDA approval involving dosing of a PDT photosensitizer for both lesion-directed and field-directed treatment of actinic keratosis.How to Approach a Contract Negotiation
https://practicaldermatology.com/series/pa-perspectives/how-approach-contract-negotiation/29072/In this video, Andrew Mastro, MS, PA-C, a board-certified physician assistant (PA) at the Illinois Dermatology Institute in Chicago, provides tips on how to approach a contract negotiation, including the importance of using objective data while negotiating.